Amplia Therapeutics Ltd (ATX) - Total Liabilities
Based on the latest financial reports, Amplia Therapeutics Ltd (ATX) has total liabilities worth AU$1.97 Million AUD (≈ $1.39 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Amplia Therapeutics Ltd - Total Liabilities Trend (2010–2026)
This chart illustrates how Amplia Therapeutics Ltd's total liabilities have evolved over time, based on quarterly financial data. See ATX net working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Amplia Therapeutics Ltd Competitors by Total Liabilities
The table below lists competitors of Amplia Therapeutics Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Korea Electronic Certification Authority Inc
KQ:041460
|
Korea | ₩20.07 Billion |
|
CammSys Corp
KQ:050110
|
Korea | ₩195.51 Billion |
|
TWL Holdings Bhd
KLSE:7079
|
Malaysia | RM148.38 Million |
|
AbL Diagnostics SA
PA:ABLD
|
France | €5.32 Million |
|
Routon Electronic Co Ltd
SHG:600355
|
China | CN¥147.15 Million |
|
3I Infrastructure PLC
LSE:3IN
|
UK | GBX387.00 Million |
|
Universus Photo Imagings Limited
NSE:UNIVPHOTO
|
India | Rs161.00 Million |
|
Samhwa Networks Co. Ltd
KQ:046390
|
Korea | ₩38.95 Billion |
Liability Composition Analysis (2010–2026)
This chart breaks down Amplia Therapeutics Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Amplia Therapeutics Ltd (ATX) total market value.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 19.78 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.05 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.05 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Amplia Therapeutics Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Amplia Therapeutics Ltd (2010–2026)
The table below shows the annual total liabilities of Amplia Therapeutics Ltd from 2010 to 2026.
| Year | Total Liabilities | Change |
|---|---|---|
| 2026-03-31 | AU$1.97 Million ≈ $1.39 Million |
+2.95% |
| 2025-03-31 | AU$1.91 Million ≈ $1.35 Million |
-44.20% |
| 2024-03-31 | AU$3.43 Million ≈ $2.42 Million |
+20.29% |
| 2023-03-31 | AU$2.85 Million ≈ $2.02 Million |
+8.07% |
| 2022-03-31 | AU$2.64 Million ≈ $1.87 Million |
+388.95% |
| 2021-03-31 | AU$539.13K ≈ $381.47K |
+5.58% |
| 2020-03-31 | AU$510.62K ≈ $361.30K |
-3.08% |
| 2019-03-31 | AU$526.86K ≈ $372.79K |
+88.55% |
| 2018-03-31 | AU$279.42K ≈ $197.71K |
-69.22% |
| 2017-03-31 | AU$907.87K ≈ $642.38K |
-11.97% |
| 2016-03-31 | AU$1.03 Million ≈ $729.75K |
+127.72% |
| 2015-03-31 | AU$452.90K ≈ $320.45K |
+12.18% |
| 2014-03-31 | AU$403.73K ≈ $285.67K |
+111.38% |
| 2013-03-31 | AU$191.00K ≈ $135.14K |
-92.51% |
| 2012-03-31 | AU$2.55 Million ≈ $1.80 Million |
+43.32% |
| 2011-03-31 | AU$1.78 Million ≈ $1.26 Million |
-20.18% |
| 2010-03-31 | AU$2.23 Million ≈ $1.58 Million |
-- |
About Amplia Therapeutics Ltd
Amplia Therapeutics Limited, a clinical-stage drug development company, engages in the development of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia. Its product pipeline comprises Narmafotinib (AMP945), an inhibitor of FAK, which is in 1b/2a clinical trial for pancreatic cancer; and treatment of idiopathic pulmonary fibrosis, as well as ovarian cancer. It also develo… Read more